The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Biological correlative analyses and updated clinical data of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR-T cell therapy, in lenalidomide (len)-refractory patients (pts) with progressive multiple myeloma (MM) after 1–3 prior lines of therapy (LOT): CARTITUDE-2, cohort A.
 
Hermann Einsele
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Novartis; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb; Celgene (Inst); Janssen (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Takeda; Takeda
 
Adam D. Cohen
Consulting or Advisory Role - AstraZeneca; Bristol Meyers Squibb; Celgene; GlaxoSmithKline; Janssen Oncology; Novartis; Oncopeptides; Roche/Genentech; Seagen; Takeda
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - Patents related to CAR T cells and biomarkers of Cytokine Release Syndrome
Expert Testimony - Janssen Oncology
Travel, Accommodations, Expenses - Celgene; GlaxoSmithKline; Janssen Oncology; Janssen Oncology; Takeda
 
Michel Delforge
Honoraria - Amgen; Celgene; Janssen
Consulting or Advisory Role - Amgen; Amgen; Celgene; Janssen
 
Jens Hillengass
Employment - Roswell Park Cancer Institute
Honoraria - Adaptive Biotechnologies; Amgen; Janssen Biotech; Takeda
Consulting or Advisory Role - Axxess Networks; Bristol-Myers Squibb/Celgene; GlaxoSmithKline; Intellisphere; Janssen Biotech; Oncopeptides; Sanofi; Skyline Diagnostics
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; Janssen Biotech; Rocket Medical; Takeda
 
Hartmut Goldschmidt
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Chugai Pharma; GlaxoSmithKline; Janssen-Cilag; Novartis; Sanofi
Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma Europe (Inst); Incyte (Inst); Janssen (Inst); Molecular Partners (Inst); MSD (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Janssen-Cilag; Sanofi
Other Relationship - Amgen (Inst); Celgene/Bristol-Myers Squibb (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Sanofi (Inst)
 
Katja Weisel
Honoraria - Abbvie; Adaptive Biotechnologies; Amgen; Amgen (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene (Inst); Celgene; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline (Inst); Janssen (Inst); Janssen-Cilag; Karyopharm Therapeutics; Novartis; Oncopeptides; Pfizer; Roche; Sanofi; Sanofi (Inst); Takeda
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Karyopharm Therapeutics; Oncopeptides; Roche; Sanofi; Takeda
Research Funding - Amgen (Inst); Bristol-Myers Squibb/Celgene (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Janssen-Cilag (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Celgene; GlaxoSmithKline; Janssen-Cilag; Takeda
 
Marc-Steffen Raab
Honoraria - Abbvie; Bristol-Myers Squibb; GlaxoSmithKline; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Oncopeptides; Pfizer; Sanofi
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Sanofi
 
Christof Scheid
Honoraria - Amgen; Bristol-Myers Squibb/Celgene; Janssen Oncology; Novartis; Pfizer; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb/Celgene; Janssen Oncology; Roche
Research Funding - Janssen Oncology (Inst); Novartis (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb/Celgene; Janssen Oncology
 
Jordan Mark Schecter
Employment - Janssen Oncology
Stock and Other Ownership Interests - Janssen Oncology
 
Kevin C. De Braganca
Employment - Janssen Research & Development
 
Helen Varsos
Employment - Janssen Research & Development
Stock and Other Ownership Interests - Johnson & Johnson
 
Tzu-min Yeh
Employment - Janssen Research & Development
 
Pankaj Mistry
Employment - Janssen
Stock and Other Ownership Interests - Janssen
 
Tito Roccia
Employment - Johnson & Johnson
Stock and Other Ownership Interests - Johnson & Johnson
 
Christina Corsale
Employment - Janssen
Stock and Other Ownership Interests - Bristol Myers Squibb Foundation
 
Muhammad Akram
Employment - Legend Biotech
Stock and Other Ownership Interests - Legend Biotech
Honoraria - Legend Biotech
Travel, Accommodations, Expenses - Legend Biotech
 
Lida Bubuteishvili-Pacaud
Employment - Legend biotech
Stock and Other Ownership Interests - Legend Biotech
 
Tonia Nesheiwat
Employment - Legend Biotech
Stock and Other Ownership Interests - Legend Biotech
 
Mounzer E. Agha
No Relationships to Disclose
 
Yael C. Cohen
Honoraria - Amgen; GlaxoSmithKline; Janssen; Medison; Medison; NeoPharm; Takeda
Consulting or Advisory Role - Amgen; GlaxoSmithKline; Janssen; Medison
Research Funding - Amgen (Inst); Karyopharm Therapeutics (Inst); Takeda (Inst)